Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Shionogi & Co ( (JP:4507) ) is now available.
Shionogi & Co., Ltd. has entered into an absorption-type company split agreement with Japan Tobacco Inc. to acquire its pharmaceutical business. This strategic move, effective December 25, 2025, aims to enhance Shionogi’s market position by integrating Japan Tobacco’s pharmaceutical operations, potentially impacting stakeholders by expanding Shionogi’s product offerings and market reach.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen2900.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, known for developing and marketing pharmaceutical products. The company focuses on creating innovative treatments and solutions in the healthcare industry.
Average Trading Volume: 2,243,111
Technical Sentiment Signal: Buy
Current Market Cap: Yen2345.3B
See more data about 4507 stock on TipRanks’ Stock Analysis page.